Severe Visual Impairment Following CAR T-Cell Therapy in Two Individuals with Malignant Optic Nerve Infiltration

ABSTRACT

We report two patients who displayed evidence of localized ocular inflammation after CAR T-cell infusion. To manage the resulting severe visual impairment, systemic corticosteroids were administered to both patients. This treatment led to a reduction in local inflammation and restored vision in one of the patients.

KEYWORDS:

• CAR T-cell therapy
• leukemic optic nerve infiltration
• malignant optic nerve infiltration
• optic nerve compartment
• tumor pseudoprogression

Disclosure statement

No potential conflict of interest was reported by the author(s).

Financial disclosure

Prof. Dr med. Stephan Thurau: Speaker honoraria from Novartis Pharma GmbH, Bayer AG, Pharm-Allergan GmbH, Panoptes GmbH, Vienna, Alimera Science Ophthalmologie, Berlin.

Univ. Prof. Dr med. Siegfried Priglinger: Speaker honoraria and travel reimbursement from Carl Zeiss Meditec AG, Novartis Pharma GmbH, Bayer AG, Pharm-Allergan GmbH, Oculentis OSD Medical GmbH, Örtli GmbH, B&L, Vitreq.

Dr med. Paul Foerster: None.

Pierre-Maurice Herr: None.

Victor Brantl: None.

Data availability statement

All data and examination findings are stored in accordance with the data protection guidelines of the LMU.